• Jupiter Endovascular

  Participated · Series B · Oct 2025

  Jupiter Endovascular is creating a new class of endovascular procedures that use its proprietary Transforming Fixation (TFX) technology, which can flexibly navigate vasculature and then pressurize to stabilize at the treatment site. The technology is integrated into the company’s Vertex catheter system, which just received FDA 510(k) clearance. Initial clinical focus is pulmonary embolism: the SPIRARE I first-in-human study treated 10 intermediate-risk PE patients in Europe and results will be presented at TCT 2025, while the pivotal SPIRARE II trial is enrolling up to 145 patients across up to 25 U.S. and European sites. Beyond pulmonary embolism, Jupiter plans to extend TFX to additional high-need cardiovascular applications. Proceeds from its latest financing will fund completion of SPIRARE II, commercialization preparations, and pipeline expansion. The oversubscribed Series B, which exceeded its $40 million target, positions the company to advance toward market launch; no revenue or user figures have been disclosed.

• Breakthrough

  Led · Seed · Feb 2025

  Founded in late 2024 by former Google executive Adit Abhyankar, Breakthrough offers an AI-driven platform that optimizes B2B storytelling and sales messaging in real time. The platform generates customized content for outbound and inbound marketing as well as sales interactions, and it optimizes context and prompts used in large language models to improve relevance, tone, and brand alignment. Its self-learning model continuously learns from every customer interaction, differentiating it from static-template AI tools and enabling deep integration with enterprise workflows. Breakthrough highlights brand-safe personalization to address enterprise adoption and already counts Fortune 500 companies among its customer base. The company cites a customer example where a prospect research task fell from three hours to two minutes using the platform. New funds will be used to expand the enterprise client base, explore applications beyond traditional sales outreach, and further refine the product to better fit market needs.

• Biolinq

  Participated · Equity · Apr 2024

  Biolinq is a healthcare technology company developing precision intradermal biosensors to improve metabolic health. Its initial product is a wearable biosensor patch with an array of tiny electrochemical microsensors that measure glucose continuously just beneath the skin’s surface, providing real-time feedback via a color-changing indicator light on the upper forearm. The device is designed to combine glucose monitoring with activity and sleep information to support people with Type 2 diabetes not on insulin. Biolinq’s platform is positioned for future multi-analyte sensing capabilities and the company says it has spent the last decade developing the underlying technology. The company recently completed a US pivotal trial and submitted for regulatory review; its intradermal glucose sensor remains investigational and is not yet FDA cleared. A $100 million Series C will finance the company’s push from development toward commercial readiness as it pursues US regulatory approval; Biolinq is headquartered in San Diego. Biolinq develops a wearable patch that uses an array of tiny electrochemical microsensors placed in the intradermal space to measure glucose and relative activity from just beneath the skin surface. The device is designed for simplicity and user feedback, with an intuitive on-device display that notifies users when glucose is within or outside target ranges. Its sensor array is engineered for redundancy, reliability and multi-analyte capabilities without the use of introducer needles or bleeding. Biolinq describes the intradermal glucose sensor as investigational and not yet cleared or approved by the FDA. The company is headquartered in San Diego, CA. Proceeds from the completed financing will fund completion of a U.S. pivotal clinical trial this year and support a subsequent FDA submission. Biolinq is developing a wearable biosensor platform whose first product is a needle-free, intelligent continuous glucose sensor with a novel integrated display on the device. The device leverages semiconductor-industry innovation to miniaturize electrochemical sensors into a micro-array of miniature biosensors roughly 25 times smaller than conventional glucose sensors, enabling redundant measurements for reliability. Early feasibility studies demonstrated the microarray patch can track glucose continuously for up to seven days in people with diabetes. Biolinq’s approach includes multiplexed sensing capabilities and immediate biosensor feedback designed to simplify diabetes management and support future consumer health and wellness applications. The company is advancing clinical, regulatory, manufacturing and commercialization milestones to expand the sensing category. Financially, Biolinq completed a $100 million Series B financing, described as a record private capital raise in the continuous glucose monitoring space, with a broad syndicate of strategic and financial investors. Biolinq is developing a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes interstitial fluid to provide actionable health information. Its first commercial product aims to let people with diabetes continuously monitor blood glucose without the pain and hassle of traditional continuous glucose monitoring systems. The platform is wirelessly enabled and designed to simultaneously measure multiple biomarkers, enabling a pipeline of biomonitoring products. Biolinq plans to use new financing to support growth of its technology platform and to fund additional clinical studies. The company completed its first clinical study in 2018 and reports promising initial clinical results. Biolinq was founded in 2012 and is located in San Diego. Biolinq develops a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes biomarkers in interstitial fluid. Its wirelessly-enabled, nickel-sized biosensor patch is designed to continuously monitor multiple biomarkers and its first commercial product targets blood glucose monitoring without the pain and hassle of traditional CGM systems. The company emphasizes factory calibration (no finger sticks), low cost-of-goods, high manufacturing uniformity, and ease of use. Biolinq intends to leverage its novel manufacturing approach to increase access to CGM and simplify diabetes management. The platform’s ability to simultaneously measure multiple biomarkers supports plans to build a pipeline of additional biomonitoring products. Biolinq was founded in 2012 (as Electrozyme, LLC) and is located in San Diego.

• Tasso

  Participated · Series B · Dec 2021

  Tasso develops clinical‑quality, virtually painless blood collection devices paired with an integrated logistics platform to enable decentralized health testing for pharma, research, and healthcare customers. Its products allow users to collect blood at convenient times and locations, increasing access to remote populations and reducing clinic visit burdens. The company’s devices are used in decentralized clinical trials, clinical research, and remote patient monitoring globally. Tasso plans to use new capital to scale manufacturing and operations to meet rising demand for at‑home testing driven by the COVID‑19 pandemic. The company emphasizes partnerships with pharmaceutical companies, academic institutions, and payers to deliver actionable health data. Tasso is headquartered in Seattle, Washington and is privately held. Tasso develops clinical-grade, at-home self-sampling blood-collection devices called Tasso OnDemand that enable virtually painless blood collection with a push-button workflow. Collected samples are mailed to CLIA-certified, high-complexity laboratories for analysis. The products are being validated for routine diagnostics, chronic disease monitoring, infectious disease surveillance, athletic and sports testing, virtual clinical trials, global health, and care for underserved populations, and are being adopted by academic medical institutions, government agencies, comprehensive cancer centers, and pharmaceutical organizations. Tasso plans to scale manufacturing and operations to meet growing demand and to enhance the platform with new value-added services. The company is headquartered in Seattle and is privately held, funded by grants, private investments, and co-development collaborations. Tasso recently completed an oversubscribed $17 million Series A and has raised $38.6 million in total to date. Tasso develops Tasso OnDemand, a self-collection blood-sampling product that lets people collect blood at home and mail samples to labs for analysis. The company positions the product to improve drug development and clinical care by enabling frequent measurement of blood markers. Tasso expects Tasso OnDemand to be available for purchase in Q2 2019 and plans to scale the product and grow the team to meet commercial demand. The business has attracted commercial interest from pharmaceutical and lab partners and pursues co-development deals with industry leaders. Tasso is privately held and headquartered in Seattle, Washington. Its technology development was supported by $13.1 million in grant funding from DARPA, DTRA, and the NIH.

• AIStorm

  Participated · Series B · Dec 2020

  AIStorm is a pioneer of AI-in-Sensor processing that accepts charge directly from sensors (pixels or MEMS microphones) and performs charge-domain analog computation to run convolutional neural networks at the sensor. Its charge-switched analog approach multiplies charge directly, enabling MAC efficiencies up to several thousand TOPS per watt and minimizing the need for external components. The technology targets ultra-low-power, ultra-low-latency always-on edge use cases across imaging and audio, including facial recognition, access control, behavioral tracking, people counting, object tracking, and segmentation. AIStorm positions its solution for battery-operated devices such as cell phones, TV remotes, laptops, home security, and authentication systems. To accelerate commercialization and market access, AIStorm has strategic partnerships with AsusTek, Egis Technology, Knowles Corporation, and Meyer Corporation. The company is headquartered in Houston, Texas, with offices in Graz, Budapest and Hsinchu. AIStorm is a pioneer in high-performance AI-in-sensor processing that operates on sensor data in its native analog form to avoid digitization. Its approach enables real-time edge processing, reducing latency and power consumption while claiming five- to ten-fold cost savings versus GPUs. The technology targets applications where fast reaction and low power are critical, with explicit relevance to advanced driver-assistance systems and mobile devices. Company executives say the architecture allows intelligent pruning of sensor data streams in real time, keeping up with massive sensor inputs. AIStorm is headquartered in Silicon Valley with offices in Phoenix and Graz, Austria, and its team includes industry veterans from leading semiconductor firms. The company recently closed a $13.2 million Series A to accelerate engineering and go-to-market efforts.

No current team members are available.